US equities |
MU $1,078.20 ▲+3.12% SNDK $1,723.06 ▲+3.77% NVDA $237.07 ▼-0.90% AMD $643.04 ▼-0.98% SPCX $167.78 ▼-2.41% INTC $113.11 ▲+0.54% TSLA $375.74 ▼-1.30% AAPL $335.71 ▲+0.62%
FinancialContent

Shattuck Labs, Inc. - Common Stock (NQ:STTK)

5.755 -0.105 (-1.79%)
Delayed Quote Updated: 12:40 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Shattuck Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming December Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Assessing Shattuck Labs: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
Assessing Shattuck Labs: Insights From 6 Financial Analysts ↗
 
Via Benzinga
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK, NY - (NewMediaWire) - October 04, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
NEW YORK, NY - (NewMediaWire) - October 03, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
NEW YORK, NY - (NewMediaWire) - October 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline ↗
Shattuck Labs shifts focus to SL-325 after modest survival improvements in a Phase 1 trial for HR-MDS and TP53m AML. The company plans workforce reductions and expects cash reserves to last into 2027. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024 ↗
STTK stock results show that Shattuck Labs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
From Shattuck Labs, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >